Bone-Specific Alkaline Phosphatase (BSAP)

The reason this test exists at all is that the standard alkaline phosphatase is a blend. Most of it comes from the liver and the bone, and a raised total cannot say which. The everyday tool for sorting that out is GGT, an enzyme that tracks the liver and ignores bone, so the parent ALP page covers how the liver-versus-bone question gets answered. BSAP takes a different route to the same goal: instead of inferring the source, it tries to measure the bone form directly.

Cleveland Clinic describes an ALP isoenzyme test that can tell which part of the body a raised enzyme came from, because liver damage and bone disorders produce chemically different forms of it. BSAP is that idea aimed squarely at the skeleton. It is reached for in specific situations rather than ordered routinely:

A high BSAP means bone is being remodeled quickly. In Paget's disease the remodeling is the whole problem: NIAMS describes a skeleton that loses bone faster than normal and then rebuilds it badly, so the building activity runs hot and the enzyme runs high. A fracture knitting back together lifts it too, as new bone forms at the break. An overactive parathyroid drives turnover up by pulling calcium out of the skeleton, and the bone responds by remodeling hard. In children the same high reading is simply growth, the same reason a teenager's total ALP runs well above an adult's.

What a high value does not directly tell you is how strong or dense the bone is. Fast turnover can accompany weak bone, but the two are separate measurements, which is why a worrying BSAP usually prompts imaging or a density scan rather than a conclusion on its own.

The honest caveat is in the word specific. The assays that isolate the bone form are good, not perfect. Bone and liver alkaline phosphatase are chemically close cousins, and the methods that separate them carry meaningful cross-reactivity, so a "bone" result can include a small contribution from the liver. That imperfect separation is the main reason BSAP stayed a follow-up test rather than a front-line one. For a first pass at a raised enzyme, the total ALP paired with GGT does the everyday sorting; the ALP versus GGT comparison walks through that logic. BSAP earns its place later, when the question is already known to be skeletal and the goal is to follow it closely over time.

It also is not a screening test for thin bones. NIAMS is clear that bone mineral density measured by DEXA at the hip and spine is the standard for diagnosing osteoporosis and predicting fracture risk. A turnover marker complements that picture; it does not replace it.

Bone-forming activity is read more than one way. Alongside BSAP, osteocalcin and P1NP report bone formation from other angles, while CTX reports the breakdown side, and together they make up the bone-turnover picture clinicians watch. They all answer the question of how fast, while a density scan answers how much. The supply markers, calcium, phosphorus, vitamin D, and parathyroid hormone, sit behind all of it, since bone cannot be built faster than its raw materials allow.

Because BSAP reads a rate, its real value shows over time. A single result says how busy the bone is on one day; a sequence says whether a treatment is taking hold or a disease is gathering pace. Since bone-forming activity shifts over months rather than weeks, our guide to how often to repeat a blood test covers why retesting a turnover marker too soon mostly shows noise.